Individuals with type 2 diabetes on other glucose-lowering agents (metformin, sulfonylureas, insulin) face higher hypoglycemia risk and need tighter supervision
PMCID: PMC4043295
Patrick's work, sign up for her newsletter
The upfront cost is the concern, and while the promise of reduced disease burden and medical expense is real, those savings may be years out, and many health plans are having a tough year financially
External resources Weight regain after liraglutide, semaglutide or tirzepatide (PubMed Central) Tirzepatide and metabolic adaptation in people with obesity (Cell Metabolism) Tirzepatide once weekly for the treatment of obesity (New England Journal of Medicine) Body weight reducing effects of tirzepatide review (PubMed Central) In case I do not see you, good afternoon, good evening, and good night
Eli Lilly's size and dominant position allow it to develop multiple GLP-1 medicines and to expand rapidly into many corners of the world